NasdaqGS:TECH

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. More Details


Snowflake Analysis

Proven track record with adequate balance sheet.


Similar Companies

Share Price & News

How has Bio-Techne's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TECH has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-0.9%

TECH

-2.9%

US Life Sciences

-2.4%

US Market


1 Year Return

22.5%

TECH

31.6%

US Life Sciences

12.0%

US Market

Return vs Industry: TECH underperformed the US Life Sciences industry which returned 31.6% over the past year.

Return vs Market: TECH exceeded the US Market which returned 12% over the past year.


Shareholder returns

TECHIndustryMarket
7 Day-0.9%-2.9%-2.4%
30 Day-4.5%-4.5%-6.5%
90 Day-5.7%11.7%8.4%
1 Year23.2%22.5%31.9%31.6%14.5%12.0%
3 Year104.2%100.0%83.1%81.9%34.8%25.8%
5 Year170.7%158.4%171.7%168.3%82.1%61.6%

Price Volatility Vs. Market

How volatile is Bio-Techne's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bio-Techne undervalued compared to its fair value and its price relative to the market?

40.31x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: TECH ($241.74) is trading above our estimate of fair value ($176.56)

Significantly Below Fair Value: TECH is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: TECH is good value based on its PE Ratio (40.3x) compared to the US Life Sciences industry average (40.6x).

PE vs Market: TECH is poor value based on its PE Ratio (40.3x) compared to the US market (17.5x).


Price to Earnings Growth Ratio

PEG Ratio: TECH is poor value based on its PEG Ratio (8.6x)


Price to Book Ratio

PB vs Industry: TECH is overvalued based on its PB Ratio (6.7x) compared to the US Life Sciences industry average (6x).


Next Steps

Future Growth

How is Bio-Techne forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

4.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TECH's forecast earnings growth (4.7% per year) is above the savings rate (2.2%).

Earnings vs Market: TECH's earnings (4.7% per year) are forecast to grow slower than the US market (22.9% per year).

High Growth Earnings: TECH's earnings are forecast to grow, but not significantly.

Revenue vs Market: TECH's revenue (10.3% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: TECH's revenue (10.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TECH's Return on Equity is forecast to be low in 3 years time (15.2%).


Next Steps

Past Performance

How has Bio-Techne performed over the past 5 years?

13.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TECH has a large one-off gain of $144.2M impacting its June 30 2020 financial results.

Growing Profit Margin: TECH's current net profit margins (31%) are higher than last year (13.4%).


Past Earnings Growth Analysis

Earnings Trend: TECH's earnings have grown by 13.6% per year over the past 5 years.

Accelerating Growth: TECH's earnings growth over the past year (138.8%) exceeds its 5-year average (13.6% per year).

Earnings vs Industry: TECH earnings growth over the past year (138.8%) exceeded the Life Sciences industry 14.9%.


Return on Equity

High ROE: TECH's Return on Equity (16.6%) is considered low.


Next Steps

Financial Health

How is Bio-Techne's financial position?


Financial Position Analysis

Short Term Liabilities: TECH's short term assets ($520.9M) exceed its short term liabilities ($106.7M).

Long Term Liabilities: TECH's short term assets ($520.9M) do not cover its long term liabilities ($539.7M).


Debt to Equity History and Analysis

Debt Level: TECH's debt to equity ratio (27.1%) is considered satisfactory.

Reducing Debt: TECH's debt to equity ratio has increased from 9.3% to 27.1% over the past 5 years.

Debt Coverage: TECH's debt is well covered by operating cash flow (54.9%).

Interest Coverage: TECH's interest payments on its debt are well covered by EBIT (8.1x coverage).


Balance Sheet


Next Steps

Dividend

What is Bio-Techne current dividend yield, its reliability and sustainability?

0.53%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: TECH's dividend (0.53%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.75%).

High Dividend: TECH's dividend (0.53%) is low compared to the top 25% of dividend payers in the US market (4.99%).


Stability and Growth of Payments

Stable Dividend: TECH is not paying a notable dividend for the US market, therefore no need to check if payments are stable.

Growing Dividend: TECH is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: TECH is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TECH's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average management tenure


CEO

Chuck Kummeth (60 yo)

7.42yrs

Tenure

US$11,483,782

Compensation

Mr. Charles R. Kummeth, also known as Chuck, has been the Chief Executive Officer and President of Bio-Techne Corporation since April 1, 2013 and served as its Chief Financial Officer since January 2014. M ...


CEO Compensation Analysis

Compensation vs Market: Chuck's total compensation ($USD11.48M) is above average for companies of similar size in the US market ($USD7.46M).

Compensation vs Earnings: Chuck's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Charles Kummeth
CEO, President & Director7.42yrsUS$11.48m0.42%
$ 39.1m
James Hippel
Executive VP of Finance & CFO6.42yrsUS$3.16m0.024%
$ 2.2m
Brenda Furlow
Senior VP2.67yrsUS$1.82m0.013%
$ 1.3m
N. Eansor
President of Protein Sciences Segment6.17yrsUS$2.69m0.0034%
$ 318.8k
Kim Kelderman
President of Diagnostics & Genomics2.42yrsUS$2.18m0.0043%
$ 403.6k
David Clair
Senior Director of Investor Relations & Corporate Developmentno datano datano data
Gerry Andros
Vice President of Sales and Marketingno datano datano data
Struan Robertson
Vice President of Human Resources5.08yrsno datano data
Robert Gavin
Senior Vice President of Analytical Solutions Division0.17yrUS$1.37mno data
Kevin Gould
Senior Vice President of Diagnostics Reagents Division0.17yrUS$1.10mno data
Luca Cicchetti
Managing Director4.17yrsno datano data
Kevin Smyth
Chief Digital Officer2.67yrsno datano data

3.4yrs

Average Tenure

54yo

Average Age

Experienced Management: TECH's management team is considered experienced (3.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Charles Kummeth
CEO, President & Director7.42yrsUS$11.48m0.42%
$ 39.1m
Robert Baumgartner
Independent Chairman of the Board7.83yrsUS$385.43k0.024%
$ 2.2m
John Higgins
Independent Director11.33yrsUS$298.76k0.010%
$ 972.1k
Joseph Keegan
Independent Director3.67yrsUS$273.76k0.0045%
$ 422.2k
Harold Wiens
Independent Director6.33yrsUS$273.76k0.013%
$ 1.2m
Randolph Steer
Independent Director30.67yrsUS$291.26k0.012%
$ 1.1m
Roeland Nusse
Independent Directorno dataUS$288.76k0.032%
$ 3.0m
John Denu
Member of Scientific Advisory Boardno datano datano data
Sachdev Sidhu
Member of Scientific Advisory Boardno datano datano data
S. J. Vessey
Independent Director1.25yrsUS$335.19k0.0017%
$ 155.7k
Alpna Seth
Independent Director3.67yrsUS$273.76k0.0045%
$ 422.2k
David Artis
Member of Scientific Advisory Boardno datano datano data

6.9yrs

Average Tenure

64yo

Average Age

Experienced Board: TECH's board of directors are considered experienced (6.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Bio-Techne Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bio-Techne Corporation
  • Ticker: TECH
  • Exchange: NasdaqGS
  • Founded: 1976
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$9.321b
  • Shares outstanding: 38.56m
  • Website: https://www.bio-techne.com

Number of Employees


Location

  • Bio-Techne Corporation
  • 614 McKinley Place NE
  • Minneapolis
  • Minnesota
  • 55413
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TECHNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 1989
TE1DB (Deutsche Boerse AG)YesCommon StockDEEURFeb 1989

Biography

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The co ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/26 06:23
End of Day Share Price2020/09/25 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.